4 911

Cited 0 times in

The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.

DC Field Value Language
dc.contributor.author김세헌-
dc.contributor.author김효송-
dc.contributor.author조병철-
dc.contributor.author최은창-
dc.contributor.author고윤우-
dc.contributor.author김주항-
dc.contributor.author김건민-
dc.contributor.author김한상-
dc.contributor.author김선미-
dc.contributor.author김혜련-
dc.date.accessioned2014-12-19T16:36:56Z-
dc.date.available2014-12-19T16:36:56Z-
dc.date.issued2012-
dc.identifier.issn0344-5704-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/89863-
dc.description.abstractPURPOSE: To assess the clinical activity and toxicity of a combination chemotherapy regimen of S-1 and cisplatin in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in a retrospective study. METHODS: A total of 49 patients were treated in an outpatient setting with S-1 80 mg/m(2) on days 1-14 and with cisplatin 70 mg/m(2) on day 1 every 3 weeks for a maximum of six cycles as a first-line palliative chemotherapy. Patients who achieved complete response (CR), partial response (PR) or stable disease (SD) after six cycles received S-1 monotherapy as a maintenance therapy. RESULTS: The median patient age was 55 years (range 33-79), 89.8 % were male, and the Eastern Cooperative Oncology Group performance status distribution was 0/1/2 (20.4 %/73.5 %/6.1 %). Of the 43 evaluable patients, 2 (4.1 %) achieved CR and 20 (40.8 %) had a PR, for an overall response rate of 44.9 %. Thirteen patients (26.6 %) had SD. The median number of chemotherapy treatments was 4 (range 1-18). Nine patients received maintenance S-1 monotherapy after six cycles of combination chemotherapy. With a mean 10.5 months (range 1.3-25.1) of follow-up, the median progression-free and overall survival were 4.5 (95 % CI, 3.7-5.3 months) and 10.8 months (95 % CI, 5.9-15.6 months), respectively. The main grade 3-4 toxicities were neutropenia (37 %), anemia (16 %) and general weakness (8 %). Other toxicities, including nausea/vomiting, mucositis and neuropathy, were mostly grade 1-2 and easily manageable. CONCLUSIONS: The combination of S-1/cisplatin therapy had a favorable efficacy with manageable toxicity as a first-line chemotherapy regimen for advanced head and neck squamous cell carcinoma patients.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfCANCER CHEMOTHERAPY AND PHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCarcinoma, Squamous Cell/drug therapy*-
dc.subject.MESHCarcinoma, Squamous Cell/mortality-
dc.subject.MESHCarcinoma, Squamous Cell/pathology-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHCisplatin/adverse effects-
dc.subject.MESHDrug Combinations-
dc.subject.MESHFemale-
dc.subject.MESHHead and Neck Neoplasms/drug therapy*-
dc.subject.MESHHead and Neck Neoplasms/mortality-
dc.subject.MESHHead and Neck Neoplasms/pathology-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHNeoplasm Recurrence, Local/drug therapy-
dc.subject.MESHOxonic Acid/administration & dosage*-
dc.subject.MESHOxonic Acid/adverse effects-
dc.subject.MESHTegafur/administration & dosage*-
dc.subject.MESHTegafur/adverse effects-
dc.titleThe efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorHan Sang Kim-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorGun Min Kim-
dc.contributor.googleauthorHyo Song Kim-
dc.contributor.googleauthorYoon Woo Koh-
dc.contributor.googleauthorSe Hun Kim-
dc.contributor.googleauthorEun Chang Choi-
dc.contributor.googleauthorYun Kyoung Hong-
dc.contributor.googleauthorJi Hee Sung-
dc.contributor.googleauthorSun Mi Kim-
dc.contributor.googleauthorJoo Hang Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.identifier.doi22868340-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00605-
dc.contributor.localIdA01202-
dc.contributor.localIdA03822-
dc.contributor.localIdA04161-
dc.contributor.localIdA00133-
dc.contributor.localIdA00945-
dc.contributor.localIdA00287-
dc.contributor.localIdA01166-
dc.contributor.localIdA00546-
dc.contributor.localIdA01098-
dc.relation.journalcodeJ00437-
dc.identifier.eissn1432-0843-
dc.identifier.pmid22868340-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00280-012-1933-8-
dc.subject.keywordHead and neck cancer-
dc.subject.keywordS-1-
dc.subject.keywordCisplatin-
dc.subject.keywordRecurrent-
dc.subject.keywordMetastatic-
dc.contributor.alternativeNameKim, Se Heon-
dc.contributor.alternativeNameKim, Hyo Song-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameChoi, Eun Chang-
dc.contributor.alternativeNameKho, Yoon Woo-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameKim, Gun Min-
dc.contributor.alternativeNameKim, Han Sang-
dc.contributor.alternativeNameKim, Sun Mi-
dc.contributor.alternativeNameKim, Hye Ryun-
dc.contributor.affiliatedAuthorKim, Se Heon-
dc.contributor.affiliatedAuthorKim, Hyo Song-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorChoi, Eun Chang-
dc.contributor.affiliatedAuthorKho, Yoon Woo-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorKim, Gun Min-
dc.contributor.affiliatedAuthorKim, Hye Ryun-
dc.contributor.affiliatedAuthorKim, Sun Mi-
dc.contributor.affiliatedAuthorKim, Han Sang-
dc.citation.volume70-
dc.citation.number4-
dc.citation.startPage539-
dc.citation.endPage546-
dc.identifier.bibliographicCitationCANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.70(4) : 539-546, 2012-
dc.identifier.rimsid31951-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.